title: Bevacizumab Inhibits Angiogenesis and Inflammation in Rat Filtration Surgery Model.
abstract: Bevacizumab can be potentially applied in filtration surgery in glaucoma patients. However, its mechanism remains unclear. In order to explore it, here, we established rat filtration surgery model and treat rat with Bevacizumab. At different time points after surgery, filtering blebs were collected and subjected to angiogenesis and inflammation genes analysis. Our results found that Bevacizumab significantly improved the outcome of filtration surgery and reduced complications (P < 0.05). Furthermore, angiogenesis factor, VEGF, and inflammation factors, TGFβ1 and TGFβ2, were dramatically inhibited by Bevacizumab treatment according to analysis of real-time PCR and western blot. Altogether, our findings suggested that Bevacizumab's beneficial effects on filtration surgery were not limited to antiangiogenesis effect and anti-inflammation effects may be also involved.
authors.affiliation: Department of Ophthalmology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
authors.forename: Gangwei
authors.initials: G
authors.lastname: Cheng
authors.affiliation: International Medical Center, Chinese PLA General Hospital, Beijing, China.
authors.forename: Hang
authors.initials: H
authors.lastname: Xiang
authors.affiliation: Department of Opthalmology, Hebei Provincial Ophthalmic Hospital, Hebei, China.
authors.forename: Guoxing
authors.initials: G
authors.lastname: Yang
authors.affiliation: Department of Ophthalmology, Beijing Tongren Hospital, Capital Medical University, Beijing, China.
authors.forename: Jianmin
authors.initials: J
authors.lastname: Ma
authors.affiliation: Department of Ophthalmology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China. gangweic@163.com.
authors.forename: Jialiang
authors.initials: J
authors.lastname: Zhao
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D000068258:Bevacizumab / Q000627:therapeutic use*; D015415:Biomarkers / Q000378:metabolism; D018463:Filtering Surgery / Q000009:adverse effects / Q000379:methods*; D011183:Postoperative Complications; D051381:Rats; D017207:Rats, Sprague-Dawley; D053773:Transforming Growth Factor beta1 / Q000378:metabolism; D053781:Transforming Growth Factor beta2 / Q000378:metabolism; D042461:Vascular Endothelial Growth Factor A / Q000378:metabolism
chemical_list: D020533:Angiogenesis Inhibitors; D000893:Anti-Inflammatory Agents; D015415:Biomarkers; D053773:Transforming Growth Factor beta1; D053781:Transforming Growth Factor beta2; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab
keywords: Angiogenesis; Bevacizumab; Filtration surgery; Inflammation